1. Home
  2. MERC vs BMEA Comparison

MERC vs BMEA Comparison

Compare MERC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

HOLD

Current Price

$1.72

Market Cap

106.5M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.22

Market Cap

98.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MERC
BMEA
Founded
1968
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.5M
98.6M
IPO Year
1987
2021

Fundamental Metrics

Financial Performance
Metric
MERC
BMEA
Price
$1.72
$1.22
Analyst Decision
Hold
Strong Buy
Analyst Count
3
7
Target Price
$3.00
$8.71
AVG Volume (30 Days)
592.7K
1.4M
Earning Date
02-12-2026
11-04-2025
Dividend Yield
8.88%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,906,971,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.48
$0.87
52 Week High
$8.28
$4.23

Technical Indicators

Market Signals
Indicator
MERC
BMEA
Relative Strength Index (RSI) 39.49 42.06
Support Level $1.67 $1.03
Resistance Level $2.53 $1.22
Average True Range (ATR) 0.16 0.09
MACD -0.08 -0.02
Stochastic Oscillator 19.23 28.91

Price Performance

Historical Comparison
MERC
BMEA

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: